GlassScriptPhysician profile
Georgios Constantinou
NPI 1790030278
$15,236.68
in general payments reported to CMS, 2019-2025
68 companies · $1,463 in 2025
The $1,463 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,601 · 2020: $1,039 · 2021: $1,419 · 2022: $1,846 · 2023: $4,107 · 2024: $3,762 · 2025: $1,463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,690 · Education: $642.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,689.89 |
| Education | $642.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,513.89 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $917.64 | 2019-2025 | Opdivo, Opdualag, Onureg |
| Astrazeneca Pharmaceuticals LP | $909.72 | 2019-2025 | Lynparza, Tagrisso, Calquence |
| Astellas Pharma US INC | $897.47 | 2019-2025 | Xtandi, Padcev, Xospata |
| Janssen Biotech, INC. | $785.89 | 2020-2025 | Rybrevant, Erleada, Darzalex |
| Daiichi Sankyo INC. | $742.68 | 2019-2025 | Enhertu, Datroway |
| Pfizer INC. | $659.91 | 2019-2025 | |
| Celgene Corporation | $649.90 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Takeda Pharmaceuticals U.S.A., INC. | $631.90 | 2019-2024 | Fruzaqla, Ninlaro, Alunbrig |
| Merck Sharp & Dohme LLC | $631.14 | 2019-2024 | Keytruda, Lynparza, Welireg |
| Amgen INC. | $582.71 | 2019-2023 | Vectibix, Xgeva, Nplate |
| Seagen INC. | $494.26 | 2020-2023 | Tukysa, Tivdak, Padcev |
| Lilly USA, LLC | $485.23 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Glaxosmithkline, LLC. | $402.02 | 2020-2025 | Ojjaara, Zejula, Jemperli |
| Incyte Corporation | $326.72 | 2021-2025 | Jakafi, Monjuvi, Pemazyre |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Georgios Constantinou listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.